

Contents

Contributors

xiii

Section I General and Introductory Aspects

1. Classes, Nomenclature, and Functions of Lipids and Lipid-Related Molecules and the Dietary Lipids

Daniel Gyamfi, Enoch Ofori Awuah and Stephen Owusu

1. Introduction	3
2. Classification	3
2.1 Simple Lipids	3
2.2 Conjugated Lipids	5
2.3 Derived Lipids	6
2.4 The Invaluable Acetyl CoA	8
3. Nomenclature	8
4. Functions of Lipids	10
5. Dietary Lipids	11
5.1 Saturated and Unsaturated Fatty Acids	11
5.2 Trans Fatty Acids in Diets	11
5.3 The Digestion of Dietary Lipids	12
5.4 Absorption, Transport and the Lipoprotein Molecule	12
5.5 Some Diseases and Conditions Associated With Lipids	14
6. Conclusion	14
Summary Points	14
Key Facts of Trans Fatty Acids	15
List of Abbreviations	15
References	15

2. Lipid Metabolism: An Overview

Daniel Gyamfi, Enoch Ofori Awuah and Stephen Owusu

1. Introduction	17
2. Fatty Acid Oxidation	17
2.1 Activation of Fatty Acids	17
2.2 Translocation	18

2.3 The Reactions of β -Oxidation	18
3. Oxidation of Very Long-Chain Fatty Acids	18
4. Oxidation of Odd-Chain Fatty Acids	19
5. Oxidation of Unsaturated Fatty Acids	19
6. Energetics of Fatty Acid Oxidation	19
7. Ketogenesis and Its Importance	19
8. Fatty Acid Synthesis	20
8.1 Fatty Acid Elongation	21
8.2 Fatty Acid Desaturation	21
8.3 Essential Fatty Acid Synthesis	21
9. Regulation of Fatty Acid Oxidation and Synthesis	21
10. Triacylglycerol Biosynthesis	22
11. Biosynthesis of Membrane Phospholipids	22
11.1 Glycerophospholipids	22
11.2 Sphingolipids	24
11.3 Glycolipids	25
11.4 Breakdown of Phospholipids and Glycolipids	26
11.5 Defects in the Metabolism of Sphingolipids and Glycolipids	27
12. Synthesis of Eicosanoids	27
13. Cholesterol Biosynthesis	27
14. Conclusion	27
Summary Points	29
Key Facts of Fatty Acid Oxidation	29
List of Abbreviations	30
References	31

3. Absorption of Dietary Fat and Its Metabolism in Enterocytes

Alicia L. Carreiro and Kimberly K. Buhman

1. Introduction	33
2. Long-Chain Fatty Acid and 2-Monoacylglycerol Uptake and Transport in Enterocytes	33
3. Intestinal TAG Synthesis	34
3.1 The MAG Pathway	34
3.2 The G3P Pathway	35
4. CM Synthesis and Secretion	35
5. CLD Synthesis and Mobilization	37
5.1 CLD Synthesis and Growth	37

5.2	CLD Mobilization	38	2.1	NPC1L1 in Cholesterol Absorption	66
5.3	Cytoplasmic Lipolysis	38	2.2	CD36 in Cholesterol Absorption	67
5.4	Lipophagy	39	2.3	SR-BI in Cholesterol Absorption	68
5.5	Fate of TAG Mobilized From CLDs	39	2.4	ABCG5/G8 in Cholesterol Absorption	68
6.	Dietary Fat Absorption During Development	40	2.5	ABCA1 in Cholesterol Absorption	68
7.	Clinical Conditions of Altered Dietary Fat Absorption	40	3.	Biomarkers of Cholesterol Absorption	68
7.1	Disorders of Defective CM Metabolism	40	4.	Intrinsic and Therapeutic Factors That Directly Affect Cholesterol Absorption	68
7.2	Disorders of Defective CLD Metabolism	41	4.1	Circadian Rhythm	68
7.3	Short Bowel Syndrome	41	4.2	Genetics	69
7.4	Cystic Fibrosis	41	4.3	Metabolic Factors	72
7.5	Obesity	42	5.	Conclusion and Final Remarks	72
7.6	Bariatric Surgery	42		Definitions of Words and Terms	73
7.7	Other Factors	42		Key Facts in Cholesterol Absorption	73
8.	Conclusion	42		Summary Points	73
	Summary Points	44		References	74
	Key Facts	44	6.	Role of Cholesterol in Maintaining Asymmetric Distribution of Phosphatidylserine in Plasma Membranes	
	Definition of Words and Terms	44		<i>Nobuto Arashiki and Yuichi Takakuwa</i>	
	Abbreviations	45	1.	Introduction	77
	References	45	1.1	Functions of Cholesterol and Phosphatidylserine	77
4.	Dietary Lipids and Enteric Infection in Rodent Models		1.2	Regulatory Mechanisms of Asymmetric PS Distribution	77
	<i>Candice Quin and Deanna L. Gibson</i>		2.	Erythrocytes	78
1.	Introduction	49	2.1	Physiological Significance	78
2.	Dietary Lipids and Host Immunity	50	2.2	Regulation of Asymmetric Distribution of PS: A Novel Function of Cholesterol	79
3.	Dietary Lipids, the Microbiome, and Inflammation	52	3.	Platelets	82
4.	Fatty Acids and Pathogen Virulence	54	4.	Apoptotic Cells	82
5.	Dietary Lipids and Enteric Disease	54	5.	Deficiency of ATP11C: An Innate Insurance for Flipping Activity	83
5.1	Enterohemorrhagic & Enteropathogenic <i>E. coli</i>	56	6.	An Appropriate Choice of Scramblase From Three Candidates	84
5.2	<i>Campylobacter jejuni</i>	56	7.	Final Remarks	84
5.3	<i>Vibrio cholerae</i>	59		Summary Points	84
5.4	<i>Listeria monocytogenes</i>	59		Key Facts of Asymmetric Phosphatidylserine Distribution and Its Regulation	85
5.5	<i>Clostridium difficile</i>	60		Definitions of Words and Terms	85
5.6	<i>Salmonella</i>	60		References	85
5.7	Rotavirus	61	7.	Subcellular Organelles: Lipid Droplets and the Multifunctional Roles	
6.	Conclusion	62		<i>Penghui Lin and Donghua H. Zhou</i>	
	Summary Points	62	1.	Introduction	87
	Key Facts of Enteric Infection in Mice	62	2.	Structure Features	87
	Definition of Words and Terms	62	3.	Formation and Expansion of Lipid Droplets	88
	Abbreviations	62	3.1	Overview	88
	References	62	3.2	Neutral Lipid Synthesis and Phospholipid Remodeling	89
5.	An Overview of Cholesterol Absorption				
	<i>Isabel Andrade, Lélita Santos and Fernando Ramos</i>				
1.	Introduction	65			
2.	Cholesterol Absorption and Its Determinants	65			

3.3 Protein Assembly	90	1.6 Polyunsaturated Fatty Acids and CRP Levels	126
3.4 Lens Formation and Droplet Budding	94	2. Conclusion	127
3.5 Droplet Expansion and Phospholipid Synthesis	94	Summary Points	128
4. Droplet Degradation	95	Mini Dictionary of Terms	128
5. Biological Functions	95	List of Abbreviations	129
Summary Points	97	References	129
Mini Dictionary of Words and Terms	97		
References	97		
8. Lipid Pathway in Liver Cells and Its Modulation by Dietary Extracts		10. Glycemic Index Meal Feeding and Lipid Profiling	
<i>Chan Yoon Park and Sung Nim Han</i>		<i>Ruirui Gao and Philip D. Chilibeck</i>	
1. Introduction	103	1. Introduction	135
1.1 Lipid Pathways in the Liver	103	2. Acute Effects of Glycemic Index on Blood Lipids	136
1.2 Abnormal Lipid Metabolism in the Liver	104	3. Effects of Chronic Consumption of Foods Differing in Glycemic Index on Blood Lipids	138
2. Regulatory Factors for Liver Lipid Metabolism	105	3.1 Effects of Chronic Consumption of Foods Differing in Glycemic Index on HDL Levels	138
2.1 Regulatory Enzymes	105	3.2 Effects of Chronic Consumption of Foods Differing in Glycemic Index on LDL Levels	141
2.2 Transcription Factors	106	3.3 Effects of Chronic Consumption of Foods Differing in Glycemic Index on TC Levels	141
3. Modulation of Liver Lipid Pathways by Dietary Extracts	106	3.4 Effects of Chronic Consumption of Foods Differing in Glycemic Index on TG Levels	142
3.1 Resveratrol	106	4. Mechanisms by Which the Glycemic Index of Foods Impacts Blood Lipids	142
3.2 Berry Extract Polyphenol	107	4.1 Attenuated Hormone Responses by Low-GI Diets	142
3.3 Green Tea Extracts (Catechin)	108	4.2 Increased Fat Utilization	144
3.4 Curcumin	108	4.3 Decreased Inflammation by Low-GI Diets	144
3.5 Quercetin	109	4.4 Upregulation of Lipid-Related Genes by Low-GI Diets	144
3.6 β -glucan	109	5. Summary	145
4. Mechanisms of Liver Lipid Pathway Modulation by Dietary Extracts	110	Summary Points	145
4.1 Resveratrol	110	Key Facts About Glycemic Index	146
4.2 Green Tea Extracts	111	Definitions of Words and Terms	146
Summary Points	112	List of Abbreviations	147
Key Facts of Lipid Pathways	112	References	147
List of Abbreviations	113		
Acknowledgments	113		
References	114		
9. C-Reactive Protein and Fatty Acids: Public Health Concerns and Implications		11. Fatty Acids, Gut Bacteria, and Immune Cell Function	
<i>Marina Maintinguer Norde, Erica Oki and Marcelo Macedo Rogero</i>		<i>Michelle SW. Xiang, Jian K. Tan and Laurence Macia</i>	
1. Introduction	117	1. Introduction	151
1.1 Molecular Pathways Linking Dietary Fatty Acids and Inflammation	118	2. Role of Fatty Acids on Inflammatory Response	152
1.2 Fatty Acids and CRP Levels	121		
1.3 Saturated Fatty Acid and CRP Levels	121		
1.4 Monounsaturated Fatty Acids and CRP Levels	126		
1.5 Trans fatty Acids and CRP Levels	126		

2.1 Physiological Interaction Between Fatty Acids and the Immune System	152	2. Lp(a) Regulation: Genetics versus Environment	178
3. Impact of Dietary Fatty Acids on Immune Function	153	3. Lp(a) Metabolism	179
3.1 Medium-Chain Fatty Acids	153	4. Lp(a) Relationship With Other Lipoproteins	182
3.2 Long-Chain Fatty Acids	154	Summary Points	183
3.3 Saturated Fatty Acids	154	Key Facts of Lp(a)	184
4. Role of Bacterially Derived Fatty Acids on Immune Function	155	Definition of Words and Terms	184
5. Role of Fatty Acids on Gut Microbiota Composition	156	References	185
6. MCFAs	156		
7. LCFA	157	14. Trans Fat Intake and Behavior	
8. Role of Fatty Acids in Health and Diseases	158	<i>Camila Simonetti Pase and Marilise Escobar Bürger</i>	
9. Autoimmunity	158	1. Introduction	189
10. Infection	158	2. Trans Fatty Acids: Chemical and Dietary Aspects	190
11. Allergies	159	2.1 Industrial Trans Fat	190
12. Cancer	159	2.2 Trans Fat From Ruminants	190
13. Perspective/Conclusion	159	3. Trans Fat Consumption: Influences on Offspring Behavior	191
Summary Points	160	4. Trans Fat and Depression	191
Key Facts About Gut Microbiota	160	5. Trans Fat and Dementia	192
Key Facts About Short-Chain Fatty Acids	160	6. Trans Fat and Risk Factors for Drug Addiction	193
Key Facts About Long-Chain Fatty Acids	160	7. Trans Fat and Bipolar Disorder	193
References	160	8. Conclusion	194
		List of Abbreviations	194
12. Adipose Tissue and Peritoneal Dialysis		Summary Points	195
<i>A. Rincon, L. Garcia-Puente and J.M. Lopez-Gomez</i>		Key Facts of Trans Fatty Acids	195
1. Adipose Tissue in Peritoneal Dialysis Patients	165	References	195
2. Adipose Tissue Measurement	166		
3. Consequences of Adipose Tissue Increase	167	Section II	
3.1 The Obesity Paradox	167	Molecular Biology of the Cell	
3.2 Predicting Mortality With High-Specificity Fat Tissue Analyses	168		
3.3 Insulin Resistance	168	15. Hedgehog Signaling and Liver Lipid Metabolism	
3.4 Cytokines and Adipokines	169	<i>Madlen Matz-Soja</i>	
3.5 Other Clinical Implications of Adipose Tissue in PD Patients	171	1. Introduction	201
Summary Points	172	2. Liver Zonation	201
Keywords	172	2.1 Liver Lipid Metabolism	204
Definition of Words and Terms	172	2.2 The Hedgehog Signaling	205
References	172	2.3 The Hedgehog Signaling in the Adult Liver and Beyond	206
		3. Conclusion	208
13. Molecular Nutrition Fats: Lipoprotein(a)		List of Abbreviations	209
<i>Byambaa Enkhmaa and Lars Berglund</i>		Summary Points	209
1. Lp(a) Discovery, Structure, and Composition	177	Key Facts	209
		References	210

16. White Adipose Tissue Metabolic Responses to Hypoxia

Nour Yahfoufi, Zeinab El Amine, Jean-François Mauger and Pascal Imbeault

1. Introduction	213
1.1 Definitions of Words and Terms?	213
1.2 Hypoxia and Adipose Tissue: The Hypoxia Hypothesis	214
1.3 Hypoxia and Adipocyte Metabolic Functions	215
1.4 Adipose Tissue Hypoxia and Adipogenesis	219
1.5 Hypoxia and Adipose Tissue Fibrosis	219
2. Conclusion	220
Summary Points	220
Acknowledgments	221
References	221

17. From Natural Triacylglycerols to Novel Structured Lipids Containing *n*-3 Long-Chain Polyunsaturated Fatty Acids

Paula A. Lopes, José M. Pestana, Diogo Coelho, Marta S. Madeira, Cristina M. Alfaia and José A.M. Prates

1. Introduction	225
2. Structured Lipids and Biofunctionality	226
2.1 Scale-Up Synthesis and Positional Distribution of Fatty Acids in Structured Lipids	226
2.2 Clinical Studies and Protective Outcomes of Structured Lipids	227
2.3 Human Milk Fat Analogs for Infant Formula Formulation	230
3. Concluding Remarks	230
Summary Points	231
Key Facts	232
Dictionary of Words and Terms	232
Acknowledgments	232
References	232

18. The Neurocan-cartilage Intermediate Layer Protein 2 (NCAN-CILP2) Region and Plasma Lipid Levels

Sadahiko Iwamoto

1. Introduction	237
1.1 Identification of the NCAN-CILP2 Region as a Locus Involved in Regulation of Plasma Lipid Levels	237
1.2 Replication Analysis of the Association of the NCAN-CILP2 Region With Plasma Lipid Levels	239

1.3 Discovery of NCAN-CILP2 Region as a Locus Involved in Other Traits	239
1.4 Discovery of Functional Variation in the NCAN-CILP2 Region Involved in Regulation of Both Plasma Lipid Levels and NAFLD	240
1.5 Molecular Evidence That Supports the Genetic Epidemiology	242
1.6 Possibility of Nutritional Intervention concerning TM6SF2 rs58542926 Genotypes	243

Abbreviations	244
Summary Points	244
Key Facts of TM6SF2 in VLDL Assembly	244
References	244

19. The Role of a Fatty Acid Chain Elongase, Elovl1, in Zebrafish and Its Implications for Kidney Disease in Humans

Sushil Bhandari and Seong-Kyu Choe

1. Introduction	249
2. Zebrafish ELOVL1 Is Highly Similar to Mammalian ELOVL1	252
3. Zebrafish <i>elovl1</i> Knockdown Impairs Swim Bladder Development	253
4. Alteration of Lipid Profiles and Impairment of Lipid Metabolism by Zebrafish <i>elovl1</i> Knockdown in the Developing Embryo	253
5. Zebrafish ELOVL1 Is Required for Normal Kidney Function	254
6. ELOVL1 Function and Its Possible Role in Human Kidney Diseases	255
Summary Points	257
Key Facts of Fatty Acid Chain Elongases, ELOVLs	257
Key Facts of Chronic Kidney Disease	257
Abbreviations	257
Definitions	258
Acknowledgments	258
References	258

20. Omega-3 Fatty Acids and Epilepsy

Silvia Tejada, Miquel Martorell, Xavier Capó, Josep A. Tur, Antoni Pons and Antoni Sureda

1. Introduction: Epilepsy	261
2. Introduction: Polyunsaturated Fatty Acids	262
3. Fatty Acid Chemical Structure	263
4. Omega-3 Fatty Acids and Epilepsy	264
5. Evidence of Omega-3 Fatty Acids as Antiepileptic Agents	266

Summary Points	267	Summary Points	292
Key Facts of Omega-3 Polyunsaturated Fatty Acids	267	Key Facts of Atherosclerosis	295
Key Facts of Epilepsy	267	References	296
Mini Dictionary of Terms	267		
Abbreviations	268		
Acknowledgments	268		
References	268		
21. Heterogeneity of White Adipose Tissue		23. Cholesterol Metabolism in Atherosclerosis Development	
<i>Kelvin HM. Kwok and Aimin Xu</i>		<i>Young-Hwa Goo</i>	
1. Introduction	271	1. Cholesterol-Carrying Lipoproteins Are the Major Players in Atherosclerosis Development	299
2. Physiological Role of the Adipose Organ	271	2. Macrophage/Foam Cell, a Major Immune Cell Type in the Atherosclerotic Plaque, Is Engaged in All Stages of Atherosclerosis Development	300
2.1 Anatomy of Adipose Tissue	271	3. Intracellular Cholesterol Trafficking in the Foam Cells	300
2.2 Energy Homeostasis in WAT	272	4. Cholesterol Metabolites in Atherosclerosis Development	302
2.3 Dysfunction of WAT in Obesity	272	5. The Intervention of Atherosclerosis by Targeting Cholesterol Metabolism in the Foam Cells	302
3. Molecular Mechanisms for WAT Heterogeneity	273	Key Facts	303
3.1 Rodents as Experimental Model for WAT Functions	273	Summary Points	303
3.2 Regulation of WAT Distribution	274	Definition of Words and Terms	304
3.3 Lineage and Identity of White Adipocytes	276	References	304
3.4 WAT Development and Expansion	277		
3.5 WAT Inflammation	278		
3.6 Adaptive Thermogenesis	280		
4. Clinical Relevance of WAT Heterogeneity in Obesity	281	24. Lipid Metabolism in Dyslipidemia and Familial Hypercholesterolemia	
4.1 Novel Approaches for Treating Obesity and Related Complications	281	<i>Lina Badimon and Gemma Chiva-Blanch</i>	
4.2 Metabolic Health Continuum in Obesity	281	1. Introduction	307
5. Concluding Remarks	281	2. Lipid Metabolism	307
Summary Points	283	2.1 Exogenous Metabolism	308
Key Facts of Leptin	283	2.2 Endogenous Metabolism	309
Key Facts of A-ZIP/F-1 Mouse	283	3. Dyslipidemia	309
List of Abbreviations	283	3.1 Classification	310
References	284	3.2 Nutritional Factors Modulating Dyslipidemia	311
Further Reading	288	3.3 Pharmacological Treatment of Dyslipidemia	312
		4. Familial Hypercholesterolemia	313
22. Perivascular Adipose Tissue Feature in Obesogenic Diets		4.1 Homozygous Versus Heterozygous Familial Hypercholesterolemia	315
<i>Laureane Nunes Masi, Tamires Duarte Afonso Serdan, Rui Curi and Sandro Massao Hirabara</i>		4.2 Pharmacological Treatment of FH	315
1. Introduction	289	5. Cardiovascular Risk in Dyslipidemia and Familial Hypercholesterolemia	316
2. PVAT: General Characteristics	289	6. Conclusions	316
3. PVAT and Inflammation	290	Key Facts of Dyslipidemia	317
4. PVAT and Diet-Induced Obesity	292	Summary Points	318
5. Concluding Remarks	292	Definition of Words and Terms	318
Competing Interests	292	Abbreviations	318
		References	319

25. Cyclosporin A-Induced Dyslipidemia and LDL Receptors

Maaïke Kockx and Leonard Kritharides

1. Cyclosporin A-Induced Dyslipidemia	323
2. Effect of CsA on Lipid Metabolism and Role of the LDLr	323
3. Effect of CsA-Binding to Lipoproteins	325
3.1 Effect of Lipoprotein Binding on Cellular Uptake of CsA	326
3.2 Effect of Lipoprotein Binding on Circulating CsA Levels	326
4. Treatment of CsA-Induced Hyperlipidemia	326
4.1 Diet	326
4.2 Statins	328
4.3 Fibrates and Ezetimibe	328
4.4 PCSK9 Inhibitors	329
4.5 Lowering of apoCIII	329
5. Conclusions	329
Summary Points	329
Key Facts of Cyclosporin A (CsA)	330
Definitions of Words and Terms	330
Abbreviations	330
References	331

26. Trans Fatty Acids and Mortality

Graciela E. Delgado and Marcus E. Kleber

1. TFAs: Nomenclature, Types, Synthesis	335
2. TFA: History and Use	335
3. TFA: Association With Lipids and Cardiovascular Disease	336
4. TFA: Association With Other Diseases	337
5. Regulations to Reduce the Use of TFA	337
6. TFA and Mortality	339
7. Conclusion	342
Summary Points	342
Key Facts of Trans Fatty Acids	342
References	343

27. Strategies to Counter Saturated Fatty Acid (SFA)-Mediated Lipointoxication

Amélie Bacle and Thierry Ferreira

1. Introduction	347
2. Fates of SFAs in the Cell	347
2.1 Beta Oxidation	347
2.2 Desaturation to MUFAs	348
2.3 Esterification to TAG and SEs	349
2.4 Ceramides/Sphingolipids	349
2.5 Phospholipids	350

3. The Impacts of SFAs on Cell Function:

Relevance to the Metabolic Syndrome	350
3.1 Apoptosis	350
3.2 Insulin Secretion	352
3.3 Insulin Resistance	352
3.4 Inflammation	353

4. The Mechanisms of SFA Deleterious Impacts on Cell Function

4.1 Ceramides: The Signaling Node	353
4.2 Saturated PLs: The Structural Node	354

5. Strategies to Counter SFA Impacts

5.1 Metabolic Regulation	356
5.2 Attenuation of Downstream Effects: Pharmacological Chaperones	359
5.3 Membrane Reshapers	359

6. Conclusion

Key Facts	359
Summary Points	360
Acknowledgments	360
References	360

28. Iodothyronines as Lipid-lowering Agents

Ilaria Demori, Adriana Voci and Elena Grasselli

1. Introduction	365
1.1 Iodothyronine Actions at the Cellular Level	365
1.2 Iodothyronines and Energy Metabolism	366
1.3 Iodothyronines and Adiposity	368
1.4 Iodothyronines and Hepatic Lipid Homeostasis	369
Summary Points	373
Definition of Words and Terms	373
References	373

29. Fish Oil Supplementation for Depression: Rationale and Mechanisms

Robert K. McNamara, Daniel M. Almeida and Jeffrey R. Strawn

1. Introduction	377
2. Biosynthesis and Biostatus	377
3. Relevance to Depression	378
3.1 Epidemiological Studies	378
3.2 LCn-3 PUFA Biostatus	378
3.3 Neuroimaging Studies	379
3.4 LCn-3 PUFA Supplementation Trials	379
3.5 Animal Studies	380
4. Biological Mechanisms	380
5. Implications for Clinical Practice	382

6. Summary and Conclusions	382	3.3 Neural Progenitor Cell Function	409
Summary Points	382	3.4 Induced Pluripotent Stem Cells for Biomedical Research	411
Acknowledgments	382	3.5 Cancer Stem Cells	411
Disclosures	382	4. Lipid Metabolism in Stem/Progenitor Cells	412
References	383	5. Specific Lipids Sustain the Complexity of Cell Function	413
30. Docosahexaenoic Acid (DHA): A Dietary Supplement With Promising Anticancer Potential		Summary Points	414
<i>Mehboob Ali, Rizwanul Haque and Saif Ahmad Khan</i>		List of Abbreviations	414
1. Introduction	389	References	415
2. DHA Sources	390	32. Transcriptional Factor Modulation by Lipid Peroxidation-Derived Aldehydes	
3. DHA and Cancer Research	390	<i>Ashish Saxena, Himangshu Sonowal and Kota V. Ramana</i>	
3.1 DHA Anti-Cancer Role: In Vitro Evidence	391	Guidelines for the Definition of Words and Terms	419
3.2 DHA Anti-Cancer Role: In Vivo Evidence	393	1. Introduction	419
3.3 DHA Anti-Cancer Role: Potential Clinical Implications	394	2. Lipid Peroxidation-Derived Lipid Aldehydes	420
4. Controversies About DHA Health Benefits	394	3. Implications of Lipid Aldehydes in Health and Disease	421
5. Conclusion	395	4. Modulation of Transcription Factor Activation by Lipid Aldehydes	424
Summary Points	396	5. Regulation of NF- κ B	424
References	396	6. Regulation of AP-1	425
		7. Regulation of NRF2	426
		8. Regulation of PPAR	426
		9. Regulation of CREB	426
		10. Regulation of STAT	427
		11. Regulation of E2F1 and HSF1	427
		12. Conclusions	427
		List of Abbreviations	427
		Summary Points	429
		Key Facts of 4-Hydroxynonenal	429
		References	429
		Index	433
Section III			
Genetic Machinery and Its Function			
31. Lipids Modulate Stem/Progenitor Cell Function			
<i>Reijo K��kel��, Saara Laitinen, Lotta Kilpinen and Petri Lehenkari</i>			
1. Stem/Progenitor Cells	403		
2. Methods to Study Stem/Progenitor Cell Lipid Profiles	403		
3. Lipids Modulate Stem/Progenitor Cell Function	404		
3.1 Mesenchymal Stromal Cell Function	405		
3.2 Hematopoietic Progenitor Cell Function	408		